Vildagliptin inhibits high free fatty acid (FFA)-induced NLRP3 inflammasome activation in endothelial cells
Source abstract
Abstract
Elevated free fatty acids (FFAs) are a risk factor for type 2 diabetes. Endothelial dysfunction induced by high levels of FFAs is one of the mechanisms related to the progression of diabetes. In clinical diabetes care, DPP-4 inhibitors have been shown to be effective in reducing glucose levels. In this study, we investigated the molecular mechanism of the clinically available DPP-4 inhibitor vildagliptin in the protection of FFA-induced endothelial dysfunction. Treatment of endothelial cells with vildagliptin inhibits FFA-induced cellular LDH release and generation of ROS. Vildagliptin also reverses FFA-induced reduced levels of GSH and elevated expression of the FFA-associated NAPHD oxidase protein NOX-4. Moreover, vildagliptin ameliorates the reduction in mitochondrial potential triggered by FFAs. Mechanistically, we show that vildagliptin suppresses FFA-induced expression of proteins of the NLRP3 inflammasome complex, including NLRP3, ASC, p20 and HMGB-1, and mitigates FFA-induced inactivation of the AMPK pathway. Consequently, vildagliptin inhibits production of two cytokines that are favored by NLRP3 inflammasome machinery: IL-1β and IL-18. Finally, we demonstrate that vildagliptin ameliorates FFA-induced reduced eNOS, indicating its protective role against endothelial dysfunction. Collectively, we conclude that the protective role of vildagliptin in endothelial cells is mediated via suppression of the AMPK-NLRP3 inflammasome-HMGB-1 axis pathway. These findings imply that the anti-diabetic drug vildagliptin possesses dual therapeutic applications in lowering glucose and improving vascular function.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Inflammasome and immune disorders · Peroxisome Proliferator-Activated Receptors · Adipokines, Inflammation, and Metabolic Diseases
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Anesthesiology, Henan Province People's Hospital
Department of Cardiology, Qilu Hospital of Shandong University
References (30)
Show source-provided references
1. 10.1016/S0140-6736(14)60460-810.1016/S0140-6736(14)60460-8 ↗
2. 10.1161/CIRCRESAHA.116.30899910.1161/CIRCRESAHA.116.308999 ↗
3. 10.1161/CIR.000000000000015210.1161/CIR.0000000000000152 ↗
4. 10.1055/s-2003-3978110.1055/s-2003-39781 ↗
5. 10.1172/JCI500110.1172/JCI5001 ↗
6. 10.2337/diabetes.49.11.193910.2337/diabetes.49.11.1939 ↗
7. 10.2174/1381612811319999047410.2174/13816128113199990474 ↗
8. 10.1253/circj.CJ-16-132610.1253/circj.CJ-16-1326 ↗
9. 10.1161/CIRCULATIONAHA.117.02813610.1161/CIRCULATIONAHA.117.028136 ↗
10. 10.1155/2018/508281710.1155/2018/5082817 ↗
11. 10.1016/S1097-2765(02)00599-310.1016/S1097-2765(02)00599-3 ↗
12. 10.1182/blood-2002-05-130010.1182/blood-2002-05-1300 ↗
13. 10.1152/ajprenal.00248.200910.1152/ajprenal.00248.2009 ↗
14. 10.1007/s00395-017-0663-910.1007/s00395-017-0663-9 ↗
15. 10.3109/13813455.2012.66819310.3109/13813455.2012.668193 ↗
16. 10.1007/s12012-015-9344-910.1007/s12012-015-9344-9 ↗
17. 10.1038/nm.415310.1038/nm.4153 ↗
18. 10.1038/s41419-017-0257-310.1038/s41419-017-0257-3 ↗
19. 10.1146/annurev-immunol-031210-10140510.1146/annurev-immunol-031210-101405 ↗
20. 10.1038/cmi.2015.9510.1038/cmi.2015.95 ↗
21. 10.4049/jimmunol.100080310.4049/jimmunol.1000803 ↗
22. 10.1016/j.redox.2017.03.00110.1016/j.redox.2017.03.001 ↗
23. 10.1016/j.tem.2017.10.00910.1016/j.tem.2017.10.009 ↗
24. 10.2337/db12-102510.2337/db12-1025 ↗
25. 10.1161/ATVBAHA.110.20642510.1161/ATVBAHA.110.206425 ↗
26. 10.1074/jbc.M114.55783510.1074/jbc.M114.557835 ↗
27. 10.1016/j.physbeh.2015.09.00710.1016/j.physbeh.2015.09.007 ↗
28. 10.1186/s12933-017-0503-010.1186/s12933-017-0503-0 ↗
29. 10.1186/s12931-017-0660-410.1186/s12931-017-0660-4 ↗
30. Zhaolin Z, Guohua L, Shiyuan W, et al. Role of pyroptosis in cardiovascular disease. Cell Prolif. 2018;e12563.